Beyond Antibodies: How New Grants Fuel a Precision Attack on Ewing Sarcoma

HOUSTON, TX – August 14, 2026 – In the high-stakes world of biotechnology, progress is often measured in clinical trial phases and stock valuations. Yet, some of the most profound innovations happen far from the trading floor, in labs funded by a blend of hope, philanthropy, and strategic government support. Houston-based Fannin Partners announced today it has secured two such critical grants from the Congressionally Directed Medical Research Programs (CDMRP) and The Faris Foundation to advance a novel therapy for Ewing sarcoma, a devastating pediatric cancer.

The funding propels Fannin's Raptamer-Drug Conjugate (RapDC) platform, a next-generation technology that offers a new line of attack against a disease that has seen far too little progress for far too long. This development isn't just about one company or one drug; it's a story about the intersection of cutting-edge science and the unique economic models required to tackle rare diseases.

The Devastating Reality of Ewing Sarcoma

For investors and strategists, understanding the market opportunity begins with understanding the unmet need. In the case of Ewing sarcoma, the need is dire. This aggressive cancer of the bone and soft tissue primarily strikes children and adolescents, with a median age of diagnosis of just 15. While modern combination chemotherapy has improved survival for patients with localized disease to around 70%, the outlook for those who relapse or present with metastatic disease is grim.

Survival rates for relapsed cases plummet to below 30%, and for those whose cancer returns quickly, the two-year survival can be less than 20%. These statistics represent a stark failure of therapeutic innovation for decades. The standard treatments are punishing, and for the most vulnerable patients, they are often not enough. This creates a critical gap that large pharmaceutical companies, driven by commercial incentives, have been slow to fill due to the rarity of the disease—only a few hundred cases are diagnosed in the U.S. each year.

A New Weapon: The Promise of Raptamer Technology

Fannin’s approach is to move beyond conventional methods. The company is developing a Raptamer-Drug Conjugate (RapDC) that targets IL1RAP, a receptor found on the surface of most Ewing sarcoma cells. The concept is a form of precision warfare at the cellular level, akin to the well-known Antibody-Drug Conjugates (ADCs) that have transformed parts of oncology.

However, instead of using large, complex antibodies as the guiding system, Fannin’s platform uses Raptamers—small, fully synthetic molecules. This shift is significant. The smaller size of Raptamers may allow for better penetration into dense tumors, while their synthetic nature offers a level of programmability and manufacturing consistency that can be challenging with biologically derived antibodies. This allows for precise, site-specific attachment of a cytotoxic payload, creating a highly targeted weapon designed to kill cancer cells while sparing healthy tissue.

"We are grateful for the support of both the CDMRP and The Faris Foundation," said Dr. Atul Varadhachary, Fannin Managing Partner. "Children with relapsed Ewing sarcoma have seen far too little therapeutic innovation over the past several decades. These grants enable us to advance our synthetic RapDC platform toward a new generation of targeted therapies that are more precise and programmable than existing approaches."

The Crucial Role of Mission-Driven Funding

Dr. Varadhachary’s statement touches upon a fundamental market reality: the development of therapies for rare pediatric cancers is often not commercially viable on its own. This is where the story pivots from pure science to strategic financing. The backing from the CDMRP—a Department of Defense program known for funding high-impact, innovative research—and The Faris Foundation provides more than just capital; it provides validation.

The Faris Foundation’s involvement is particularly poignant. Founded by Dr. Asha Virani in memory of her son, Faris, who passed away from Ewing sarcoma, the foundation is laser-focused on funding exceptional science with the potential to transform outcomes. "At the Faris Foundation, we invest in exceptional science," stated Dr. Virani. "Fannin's team is advancing an innovative platform with the potential to transform the treatment of Ewing sarcoma. The CDMRP's support further validates the scientific promise of this work and underscores the urgent need for new treatment options for children with this devastating disease."

This type of philanthropic and government grant funding bridges a critical valley of death for therapies that are scientifically promising but commercially uncertain. It de-risks the early stages of development, allowing firms like Fannin to build a data package that can eventually attract larger private investment. Fannin has masterfully woven this into its business model, having secured over $85 million in grant funding across its portfolio of a dozen programs.

Fannin's Broader Strategy in Pediatric Oncology

This announcement is not an isolated event but a key milestone in Fannin's broader strategy. The company is building a dedicated pediatric oncology portfolio, including a clinical-stage antibody program for acute lymphoblastic leukemia and another RapDC program for osteosarcoma, which is already in IND-enabling studies. The Ewing sarcoma grant expands and diversifies this effort.

The versatility of the Raptamer platform itself is a core asset. Its modular design means that the underlying technology can be adapted to target different receptors across a range of cancers and other diseases. The external validation from these two prestigious grants will not only accelerate the Ewing sarcoma program but will likely attract further attention to the platform's potential in other therapeutic areas.

For investors scanning the 2026 landscape, the Fannin story is a powerful case study. It demonstrates how a nimble, strategically funded firm can tackle some of medicine's toughest challenges. By leveraging a hybrid funding model and focusing on a platform with broad applicability, Fannin is building a pipeline that addresses profound human needs while creating long-term value. The path forward for this Ewing sarcoma therapy is long and fraught with the typical risks of drug development, but with this new funding, a crucial step has been taken to bring a new generation of treatment to the children who need it most.